Micron Biomedical Secures $16M, Boosting Series A to $33M

• Micron Biomedical raised $16 million, bringing its Series A equity funding to over $33 million.

• The funds will support expanded manufacturing for its needle-free drug and vaccine delivery technology.

Micron Biomedical, based in Atlanta, has secured additional funding to further its mission of simplifying drug and vaccine delivery. The Series A funding round, now totalling $33 million, was co-led by J2 Ventures and the Global Health Investment Corporation (GHIC).

The company plans to use the latest investment to scale commercial manufacturing of its dissolvable microarray technology. This innovative solution eliminates the need for traditional injection methods, offering a self-administered or caregiver-administered alternative. The platform is designed to simplify transport, storage, and administration of drugs and vaccines, particularly those requiring cold storage.

The funding supplements significant recent support, including a $3.7 million grant from CEPI earlier this month. Micron also received $2 million from BARDA’s Patch Forward competition and $7.5 million from the Bill & Melinda Gates Foundation. The latter grant is earmarked to support Phase 2 clinical trials for Micron’s needle-free measles/rubella vaccine.

Micron continues to innovate in vaccine delivery, developing an mRNA-based flu vaccine with broad protection potential. “The financial investment, commercialisation experience, and scientific input of GHIC and J2 Ventures will accelerate our ability to bring needle-free medicines and vaccines to more people who either can’t access them today or prefer to receive them without an injection,” said Steve Damon, CEO of Micron Biomedical.